home / stock / srpt / srpt articles

SRPT Articles, Sarepta Therapeutics Inc. - From 01/29/24

Stock Information
Company Name: Sarepta Therapeutics Inc.
Stock Symbol: SRPT
Market: NASDAQ
Website: sarepta.com
Menu
SRPT SRPT Quote SRPT Short SRPT News SRPT Articles SRPT Message Board
Get SRPT Alerts

News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing | Benzinga

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced data from Part B of the MOMENTUM study (Study SRP-5051-201) Phase 2, multi-ascending dose tri...
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year | Benzinga

Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product revenue of $1.145 billion. The Cambridge, Mass...

Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday | Benzinga

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Acuity Brands, Inc. (NYSE: AYI) rose sharply Tuesd...

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 | Benzinga

Needham analyst forecasts a positive outlook for Arcellx Inc (NASDAQ:ACLX) in 2024, citing strong potential stemming from the anticipated pivotal...
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT | Benzinga

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securitie...

Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy | Benzinga

Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the consen...

Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There' | Benzinga

On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got...
Director of Sarepta Therapeutics Purchased $3.94M In Stock | Benzinga

Richard Barry, Director at Sarepta Therapeutics (NASDAQ:SRPT), reported a large insider buy on November 6, according to a new SEC filing. What Hap...

Sarepta Therapeutics President & CEO Makes $2.00M Stock Purchase | Benzinga

Douglas S Ingram, President & CEO at Sarepta Therapeutics (NASDAQ:SRPT), reported a large insider buy on November 6, according to a new SEC fil...

SRPT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT | Benzinga

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securitie...
Previous 10 Next 10